Table 2.
Clinical parameters associated with residual DOAC levels: multivariate logistic regression analyses stratified according to region
| Clinical parameter | Comparison | ≥30 ng/mL | ≥50 ng/mL | ||
|---|---|---|---|---|---|
| OR [95% CI] | P | OR [95% CI] | P | ||
| Low-bleeding-risk procedures | |||||
| DOAC | Dabigatran vs apixaban | 0.63 [0.47-0.84] | .0019 | 0.71 [0.45-1.14] | .1553 |
| Rivaroxaban vs apixaban | 1.0 [0.8-1.25] | .9849 | 0.42 [0.26-0.67] | .0003 | |
| Age, y | ≥75 vs <75 | 1.31 [1.06-1.62] | .0127 | 1.49 [1.03-2.17] | .0367 |
| Sex | Female vs male | 1.36 [1.1-1.68] | .004 | 1.73 [1.2-2.49] | .0034 |
| Weight, kg | 70-90 vs <70 | 0.97 [0.74-1.27] | .8122 | 0.96 [0.6-1.55] | .881 |
| >90 vs <70 | 1.1 [0.82-1.48] | .5042 | 1.33 [0.81-2.21] | .2637 | |
| CrCl, mL/min | ≥50 vs <50 | 0.65 [0.49-0.86] | .0024 | 0.56 [0.35-0.91] | .0193 |
| P-glycoprotein or CYP3A4 inhibitor | Presence vs absence | 1.08 [0.75-1.55] | .6712 | 1.15 [0.64-2.1] | .6378 |
| Active cancer | Presence vs absence | —* | —* | 1.69 [0.88-3.27] | .1167 |
| DOAC dosing | Low dose vs standard dose | 0.77 [0.59-1.01] | .0606 | 0.53 [0.32-0.86] | .0106 |
| DOAC interruption, h | <36 vs 36-48 | 1.44 [1.04-1.99] | .0262 | 1.57 [0.93-2.62] | .0888 |
| >48 vs 36-48 | 0.78 [0.8-1.01] | .0624 | 0.75 [0.44-1.28] | .2919 | |
| High-bleeding-risk procedures | |||||
| DOAC | Dabigatran vs apixaban | 0.23 [0.05-1.0] | .0504 | 0.39 [0.04-3.5] | .4027 |
| Rivaroxaban vs apixaban | 2.73 [1.56-4.8] | .0005 | 0.43 [0.08-2.36] | .3328 | |
| Age, y | ≥75 vs <75 | 0.84 [0.49-1.45] | .5411 | 1.7 [0.38-7.55] | .4838 |
| Sex | Female vs male | 1.32 [0.77-2.27] | .3137 | 5.55 [1.02-30.05] | .0469 |
| Weight, kg | 70-90 vs <70 | 0.61 [0.33-1.1] | .1014 | 0.95 [0.21-4.29] | .9476 |
| >90 vs <70 | 0.43 [0.2-0.92] | .0304 | 0.51 [0.04-6.21] | .5979 | |
| CrCl, mL/min | ≥50 vs <50 | 0.45 [0.24-0.85] | .0139 | 0.42 [0.09-1.94] | .2664 |
| P-glycoprotein or CYP3A4 inhibitor | Presence vs absence | 1.33 [0.48-3.71] | .583 | —* | —* |
| Active cancer | Presence vs absence | —* | —* | —* | —* |
| DOAC dosing | Low dose vs standard dose | 0.52 [0.28-0.98] | .0442 | 0.51 [0.11-2.41] | .3968 |
| DOAC interruption, h | <60 vs 60-72 | 1.51 [0.66-3.42] | .3279 | 0.77 [0.09-6.31] | .8054 |
| >72 vs 60-72 | 0.83 [0.47-1.46] | .5116 | 0.44 [0.05-4.16] | .4712 | |
Bold values in the table represent results that were statistically significant (P < .05).
CI, confidence interval; OR, odds ratio.
*
Dashes represent variables that were omitted from the multivariate model due to small sample sizes and minimal impact on the model.